Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical Trial

Author: Benzinga Newsdesk | September 11, 2024 09:01am

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial.

Posted In: AIM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist